...
首页> 外文期刊>Archiv der Pharmazie >SDX-308 and SDX-101, Non-Steroidal Anti-Inflammatory Drugs, as Therapeutic Candidates for Treating Hematologic Malignancies Including Myeloma.
【24h】

SDX-308 and SDX-101, Non-Steroidal Anti-Inflammatory Drugs, as Therapeutic Candidates for Treating Hematologic Malignancies Including Myeloma.

机译:SDX-308和SDX-101,非甾体类抗炎药,可作为治疗包括骨髓瘤在内的血液系统恶性肿瘤的治疗药物。

获取原文
获取原文并翻译 | 示例
           

摘要

Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti-tumor effects are thought to be related to their cyclooxygenase-2-inhibitory activity, but recent studies have shown that non-steroidal anti-inflammatory drugs exert their anti-tumor effect via cyclooxygenase-2-independent mechanism. SDX-308 (CEP-18082) is a non-cyclooxygenase-2-inhibiting indole-pyran analog and is structurally related to SDX-101, an R-enantiomer of etodolac. SDX-308 has a potent anti-myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX-308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX-308 as an anti-myeloma drug regulating increased osteoclast activity.
机译:非甾体类抗炎药已显示出抑制结肠癌的致癌作用,并诱导多种肿瘤细胞系的凋亡。人们认为某些抗肿瘤作用与其环氧合酶-2抑制活性有关,但最近的研究表明,非甾体类抗炎药通过不依赖环氧合酶-2的机制发挥抗肿瘤作用。 SDX-308(CEP-18082)是一种非环氧合酶2抑制吲哚-吡喃类似物,在结构上与依托度酸的R对映体SDX-101相关。 SDX-308具有有效的抗骨髓瘤作用,与其他药物联合使用可显示协同作用,可治疗慢性淋巴细胞性白血病。另外,SDX-308抑制破骨细胞的形成和活性,因此可能是治疗破骨细胞活性增加的疾病(如多发性骨髓瘤和转移性癌中的溶骨性病变以及骨质疏松症)的有吸引力的药物。这篇综述涵盖了SDX-308作为抗骨髓瘤药物调节破骨细胞活性增加的未来应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号